

Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the Phase 2b study

M. Maurer, A. Giménez-Arnau, V. Jain, A. Reich, CE. Ortmann, P. Walsh, S. Haemmerle

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the abstract after 11th June 2023, once it is available at the congress website